Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciences founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service, Valens, has been used to successfully sequence hundreds of antibodies without the need for B cells. Now, with Griffin, we can sequencing complex mixes of antibodies directly from patient serum, or from immunized animals.
Watch our CEO, Dr. Natalie Castellana’s presentation on Unlocking the Serum Antibody Repertoire: Accessing Functional Antibodies without B Cells to learn how Griffin works.
Click below to watch the presentation.
Related Posts
New Publication Reveals Ebolavirus-Neutralizing Monoclonal Antibodies
Abterra Biosciences, together with VUMC Vaccine Center, Mapp Bio, PNNL, UTMB Health, Ragon Institute, Integral Molecular, and La Jolla Institute, recently published a paper describing the discovery of Ebolavirus-neutralizing antibodies from convalescent plasma.Read...
Immune Repertoire Sequencing in Human
Immune repertoire sequencing enables deeper understanding of the adaptive immune response [1]. Abterra Biosciences has developed Reptor™, a flexible immune repertoire sequencing and analysis service. In this study, we analyzed the B-cell receptor (BCR) repertoire...
Clonal Hit-Expansion Case Study
Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign. Contact us to learn more about how our...
Get In Touch